Clinical biomarkers in central nervous system tumors

• Grant number: 16/15485-8
• Support Opportunities: Scholarships abroad - Research Internship - Post-doctor
• Effective date (Start): October 01, 2016
• Effective date (End): September 30, 2017
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Houtan Noushmehr
• Grantee: Camila Ferreira de Souza
• Supervisor: Steven N. Kalkanis
• Host Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
• Research place: Henry Ford Health System, United States
• Associated to the scholarship: 14/08321-3 - Identification and characterization of functional genomic elements associated with progression of low to high grade glioma: integrative study of genome and epigenome, BP.PD

Abstract

Harmful and damaging effects on global chromatin and epigenomic pattern, gene expression, and cellular phenotype has been known to be associated with cancer. The post genome-wide association studies era offers a blueprint for investigating genomics, epigenomics, and transcriptomics information together, providing us an exciting opportunity to enlighten how complex diseases develop at the whole genome level. Recurrent gliomas and meningiomas are tumors that develop in the central nervous system (CNS) and commonly exhibit failure of the gold standard therapy and unfavorable patient clinical outcome. DNA methylation changes chart the epigenome of distinct CNS tumor types. Molecular taxonomy defined by epigenome-wide studies can recapitulate abnormalities that are inherent to the epigenome of recurrent and aggressive neoplastic cells. In this proposal, our primary goal is to characterize DNA methylation alterations as leading candidates for the development of prognostication biomarkers in aggressive recurrent gliomas and meningiomas. (AU)

Scientific publications

(5)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

MAZOR, TALI; CHESNELONG, CHARLES; PANKOV, ALEKSANDR; JALBERT, LLEWELLYN E.; HONG, CHIBO; HAYES, JOSIE; SMIRNOV, IVAN V.; MARSHALL, ROXANNE; SOUZA, CAMILA F.; SHEN, YAOQING; et al. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, v. 114, n. 40, p. 10743-10748, OCT 3 2017. (16/15485-8, 14/08321-3, 15/07925-5)

MALTA, TATHIANE M.; SOKOLOV, ARTEM; GENTLES, ANDREW J.; BURZYKOWSKI, TOMASZ; POISSON, LAILA; WEINSTEIN, JOHN N.; KAMINSKA, BOZENA; HUELSKEN, JOERG; OMBERG, LARSSON; GEVAERT, OLIVIER; et al. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell, v. 173, n. 2, p. 338+, APR 5 2018. (16/06488-3, 14/08321-3, 15/07925-5, 16/01975-3, 16/01389-7, 16/15485-8, 14/02245-3, 16/10436-9, 16/12329-5)

DE SOUZA, CAMILA FERREIRA; SABEDOT, THAIS S.; MALTA, TATHIANE M.; STETSON, LINDSAY; MOROZOVA, OLENA; SOKOLOV, ARTEM; LAIRD, PETER W.; WIZNEROWICZ, MACIEJ; IAVARONE, ANTONIO; SNYDER, JAMES; et al. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. CELL REPORTS, v. 23, n. 2, p. 637-651, APR 10 2018. (14/03989-6, 16/15485-8, 16/06488-3, 14/08321-3, 16/12329-5, 16/01975-3, 14/02245-3, 15/07925-5)

ALDAPE, KENNETH; AMIN, SAMIRKUMAR B.; ASHLEY, DAVID M.; BARNHOLTZ-SLOAN, JILL S.; BATES, AMANDA J.; BEROUKHIM, RAMEEN; BOCK, CHRISTOPH; BRAT, DANIEL J.; CLAUS, ELIZABETH B.; COSTELLO, JOSEPH F.; et al. Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. NEURO-ONCOLOGY, v. 20, n. 7, p. 873-884, JUL 2018. (16/15485-8, 14/08321-3, 15/07925-5)

MALTA, TATHIANE M.; DE SOUZA, CAMILA F.; SABEDOT, THAIS S.; SILVA, TIAGO C.; MOSELLA, MARITZA S.; KALKANIS, STEVEN N.; SNYDER, JAMES; CASTRO, ANA VALERIA B.; NOUSHMEHR, HOUTAN. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. NEURO-ONCOLOGY, v. 20, n. 5, p. 608-620, MAY 2018. (16/06488-3, 16/15485-8, 14/08321-3, 16/12329-5, 16/10436-9, 15/07925-5, 16/01975-3, 14/02245-3, 16/01389-7, 16/11039-3)